Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease
Melody Smith(Memorial Sloan Kettering Cancer Center), Marcel R.M. van den Brink(City Of Hope National Medical Center), Arnab Ghosh(Memorial Sloan Kettering Cancer Center), Marco L. Davila(University of South Florida), Andrea Schietinger(Memorial Sloan Kettering Cancer Center), Scott E. James(City Of Hope National Medical Center), Enrico Velardi(Bambino Gesù Children's Hospital), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Memorial Sloan Kettering Cancer Center), Gertrude Gunset(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937